Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus.

A dose-dependent decrease in infectivity was observed on introduction of eosinophils into suspensions of respiratory syncytial virus group B (RSV-B). This antiviral effect was reversed by ribonuclease inhibitor, suggesting a role for the eosinophil secretory ribonucleases. Recombinant eosinophil-derived neurotoxin (rhEDN), the major eosinophil ribonuclease, promoted a dose-dependent decrease in RSV-B infectivity, with a 40-fold reduction observed in response to 50 nM rhEDN. Ribonucleolytically inactivated rhEDN (rhEDNdK38) had no antiviral activity. Semiquantitative reverse transcriptase-polymerase chain reaction demonstrated loss of viral genomic RNA in response to rhEDN, suggesting that this protein promotes the direct ribonucleolytic destruction of extracellular virions. Ribonuclease A had no antiviral activity even at approximately 1000-fold higher concentrations, suggesting that rhEDN has unique features other than ribonuclease activity that are crucial to its effectiveness. These results suggest that rhEDN may have potential as a therapeutic agent for prevention or treatment of disease caused by RSV.

[1]  G. Prince,et al.  Animal models of respiratory syncytial virus infection. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  H. Rosenberg,et al.  Eosinophils inhibit retroviral transduction of human target cells by a ribonuclease‐dependent mechanism , 1997, Journal of leukocyte biology.

[3]  Hicks Cb.  Update on antiretroviral therapy. , 1997 .

[4]  A. J. Wright,et al.  Recent advances in the management of human immunodeficiency virus infection. , 1997, Mayo Clinic proceedings.

[5]  K. Dyer,et al.  Diversity among the primate eosinophil-derived neurotoxin genes: a specific C-terminal sequence is necessary for enhanced ribonuclease activity. , 1997, Nucleic acids research.

[6]  R. Silverman,et al.  Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Libonati,et al.  Structure–function relationships in human ribonucleases: main distinctive features of the major RNase types , 1997, FEBS letters.

[8]  R. Garofalo,et al.  Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. , 1997, The Journal of infectious diseases.

[9]  M. V. Nogués,et al.  9 – Pancreatic Ribonucleases , 1997 .

[10]  G. Gleich,et al.  Eosinophil-Associated Ribonucleases , 1997 .

[11]  T. Ganz,et al.  Antimicrobial peptides of leukocytes , 1997, Current opinion in hematology.

[12]  W. Ardelt,et al.  Inhibition of HIV-1 Production and Selective Degradation of Viral RNA by an Amphibian Ribonuclease* , 1996, The Journal of Biological Chemistry.

[13]  D. Newton,et al.  X-ray crystallographic structure of recombinant eosinophil-derived neurotoxin at 1.83 A resolution. , 1996, Journal of molecular biology.

[14]  R. Silverman,et al.  A mammalian 2-5A system functions as an antiviral pathway in transgenic plants. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Busse,et al.  Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. Roles of CD18 and intercellular adhesion molecule-1. , 1996, Journal of immunology.

[16]  R. Zbinden,et al.  Discrimination of respiratory syncytial virus subgroups A and B by reverse transcription-PCR , 1996, Journal of clinical microbiology.

[17]  P. Hodgkin,et al.  IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. , 1996, Immunity.

[18]  R. Coombs,et al.  Virucidal effect of stimulated eosinophils on human immunodeficiency virus type 1. , 1996, AIDS research and human retroviruses.

[19]  F. Hayden,et al.  Combination antiviral therapy for respiratory virus infections. , 1996, Antiviral research.

[20]  A. Tominaga,et al.  Elevated innate peripheral blood eosinophilia fails to augment irradiated cercarial vaccine-induced resistance to Schistosoma mansoni in IL-5 transgenic mice. , 1995, The Journal of parasitology.

[21]  P. Openshaw.  Immunity and immunopathology to respiratory syncytial virus. The mouse model. , 1995, American journal of respiratory and critical care medicine.

[22]  K. Dyer,et al.  Eosinophil Cationic Protein and Eosinophil-derived Neurotoxin , 1995, Journal of Biological Chemistry.

[23]  T. Ganz,et al.  Defensins and other endogenous peptide antibiotics of vertebrates , 1995, Journal of leukocyte biology.

[24]  Fei Li,et al.  Hyperglycosylation of eosinophil ribonucleases in a promyelocytic leukemia cell line and in differentiated peripheral blood progenitor cells , 1995, Journal of leukocyte biology.

[25]  K. Dyer,et al.  Rapid evolution of a unique family of primate ribonuclease genes , 1995, Nature Genetics.

[26]  H. Rosenberg.  Recombinant Human Eosinophil Cationic Protein , 1995, The Journal of Biological Chemistry.

[27]  M. Seminario,et al.  The role of eosinophils in the pathogenesis of asthma. , 1994, Current opinion in immunology.

[28]  N. Sigurs,et al.  Eosinophil cationic protein in nasal secretion and in serum and myeloperoxidase in serum in respiratory syncytial virus bronchiolitis: relation to asthma and atopy , 1994, Acta paediatrica.

[29]  H. Rosenberg,et al.  Characterization of the eosinophil granule proteins recognized by the activation‐specific antibody EG2 , 1994, Journal of leukocyte biology.

[30]  A. Dvorak,et al.  Cytokine induction of granule protein synthesis in an eosinophil‐inducible human myeloid cell line, AML14 , 1994, Journal of leukocyte biology.

[31]  D. Newton,et al.  RNase inhibition of human immunodeficiency virus infection of H9 cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Ö. Strannegård,et al.  Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus , 1994, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[33]  D. Newton,et al.  Toxicity of an antitumor ribonuclease to Purkinje neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  S. Kayes,et al.  Depletion of eosinophils by anti-IL-5 monoclonal antibody treatment of mice infected with Trichinella spiralis does not alter parasite burden or immunologic resistance to reinfection. , 1992, Journal of immunology.

[35]  R. Garofalo,et al.  Activation of Human Eosinophils In Vitro by Respiratory Syncytial Virus , 1992, Pediatric Research.

[36]  D. Loegering,et al.  Eosinophil-derived neurotoxin and human liver ribonuclease. Identity of structure and linkage of neurotoxicity to nuclease activity. , 1992, The Journal of biological chemistry.

[37]  K. Sullivan.  Short protocols in molecular biology, 2nd Edn , 1992 .

[38]  R. Garofalo,et al.  Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. , 1992, The Journal of pediatrics.

[39]  R. L. Barker,et al.  The molecular biology of eosinophil granule proteins. , 1991, International archives of allergy and applied immunology.

[40]  R. Coffman,et al.  Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. , 1990, Journal of immunology.

[41]  R. Coffman,et al.  Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Andreas Radbruch,et al.  High gradient magnetic cell separation with MACS. , 1990, Cytometry.

[43]  R. L. Barker,et al.  Sequence of human eosinophil-derived neurotoxin cDNA: identity of deduced amino acid sequence with human nonsecretory ribonucleases. , 1989, Gene.

[44]  R. L. Barker,et al.  Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases. , 1989, Journal of immunology.

[45]  D. Tenen,et al.  Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity , 1989, The Journal of experimental medicine.

[46]  T. Ganz,et al.  Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. , 1989, Journal of immunology.

[47]  D. Tenen,et al.  Molecular cloning of the human eosinophil-derived neurotoxin: a member of the ribonuclease gene family. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Loegering,et al.  Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. , 1989, The American review of respiratory disease.

[49]  J. Sinnott,et al.  Respiratory Syncytial Virus , 1988, Infection Control & Hospital Epidemiology.

[50]  G. Gleich,et al.  Toxic effects produced or mediated by human eosinophil granule components on Trypanosoma cruzi. , 1988, The American journal of tropical medicine and hygiene.

[51]  H. Faden,et al.  Release of leukotriene C4 in respiratory tract during acute viral infection. , 1988, The Journal of pediatrics.

[52]  C. Spry.  Eosinophils : a comprehensive review, and guide to the scientific and medical literature , 1988 .

[53]  G. Gleich,et al.  DEPOSITS OF EOSINOPHIL GRANULE PROTEINS IN CARDIAC TISSUES OF PATIENTS WITH EOSINOPHILIC ENDOMYOCARDIAL DISEASE , 1987, The Lancet.

[54]  D. Loegering,et al.  Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. , 1986, Journal of immunology.

[55]  Ú. Árnason,et al.  The cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity. , 1986, Biochemical and biophysical research communications.

[56]  P. Venge,et al.  Mechanism of membrane damage mediated by human eosinophil cationic protein , 1986, Nature.

[57]  D. Loegering,et al.  Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Loegering,et al.  Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni. , 1985, The American journal of tropical medicine and hygiene.

[59]  R. Douglas,et al.  In vivo inhibition of respiratory syncytial virus by ribavirin , 1982, Antimicrobial Agents and Chemotherapy.

[60]  D. Durack,et al.  Purification of human eosinophil-derived neurotoxin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. M. Sumi,et al.  Neurotoxicity of human eosinophils. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[62]  M. Lebowitz,et al.  The relationship of childhood respiratory illness to adult obstructive airway disease. , 2015, The American review of respiratory disease.

[63]  A. Sher.  Immunity against Schistosoma mansoni in the mouse. , 1977, The American journal of tropical medicine and hygiene.

[64]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.

[65]  E. H. Lennette,et al.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. , 1969, American journal of epidemiology.

[66]  B. Zweiman,et al.  The relationship between bronchiolitis and allergic asthma. A prospective study with allergy evaluation. , 1966, The Journal of allergy.

[67]  D. J. Bauer.  Antiviral chemotherapy. , 1966, The Scientific basis of medicine annual reviews.

[68]  K. Johnson,et al.  A Plaque Assay for Respiratory Syncytial Virus , 1963, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.